Briquilimab (JSP-191) is a humanized, aglycosylated monoclonal antibody that directly inhibits the interaction between the stem cell factor (SCF) ligand and its receptor, KIT (CD117), leading to the blockade of the downstream KIT signaling pathway and ultimately inducing mast cell apoptosis; the SCF-KIT interaction is well-characterized as essential for mast cell survival, and its inhibition has been demonstrated to directly trigger mast cell apoptosis primarily through the Bim-mediated pathway, thereby removing the underlying cellular source of inflammation for many immunological and inflammatory diseases, including chronic urticaria and asthma.